文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

重症与围手术期患者的输血阈值是否应不同?随机试验的荟萃分析

Should Transfusion Trigger Thresholds Differ for Critical Care Versus Perioperative Patients? A Meta-Analysis of Randomized Trials.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论重症患者限制性输血降低30天死亡率(OR 0.82),手术患者呈相反方向(OR 1.31,未达显著),亚组交互作用显著(p=0.04)。

该荟萃分析纳入27项随机对照试验共10,797例成人重症或手术患者,比较限制性与开放性异体浓缩红细胞输血阈值,主要终点为30天全因死亡率。重症患者中限制性输血显著降低30天死亡率(OR 0.82;95%CI 0.70-0.97),手术患者中呈相反方向(OR 1.31;95%CI 0.94-1.82)。亚组交互作用检验显著(p=0.04),提示限制性输血对死亡率的影响在重症与手术患者间存在统计学差异。重症患者限制性策略还降低卒中/短暂性脑缺血发作、浓缩红细胞暴露、输血反应及住院时间;手术患者仅减少浓缩红细胞暴露。作者认为限制性输血策略的安全性在重症与围手术期患者间可能不同,需进一步开展围手术期输血策略试验。

要点

  • 重症患者限制性输血较开放性输血显著降低30天死亡率(OR 0.82;95%CI 0.70-0.97)。
  • 手术患者限制性输血对死亡率呈相反方向(OR 1.31;95%CI 0.94-1.82),未达统计学显著。
  • 亚组交互作用检验显著(p=0.04),提示重症与手术患者的效应存在统计学差异。
  • 重症患者限制性策略还降低卒中/短暂性脑缺血发作、浓缩红细胞暴露、输血反应及住院时间。
  • 手术患者限制性策略仅减少浓缩红细胞暴露,作者认为需进一步开展围手术期输血策略试验。

适用人群与场景

  • 纳入成人手术患者或危重症患者,比较异体浓缩红细胞开放性 vs 限制性输血阈值的随机对照试验。

研究设计与关键结果

  • 研究类型为随机对照试验的荟萃分析,检索Medline、EMBASE和Cochrane Library至2016年6月15日,纳入27项随机对照试验共10,797例患者。
  • 主要终点为30天全因死亡率,按手术与重症患者亚组分析;采用随机效应模型计算比值比和加权均数差,并用亚组交互作用检验评估亚组差异。
  • 重症患者中,限制性输血较开放性输血显著降低30天死亡率(OR 0.82;95%CI 0.70-0.97)。
  • 手术患者中,限制性输血对死亡率呈相反方向(OR 1.31;95%CI 0.94-1.82)。
  • 亚组交互作用检验显著(p=0.04),提示限制性输血对死亡率的影响在重症(风险降低)与手术患者(风险可能升高或无差异)间存在统计学差异。
  • 重症患者中,限制性策略降低卒中/短暂性脑缺血发作、浓缩红细胞暴露、输血反应及住院时间。
  • 手术患者中,限制性输血减少浓缩红细胞暴露。

证据类型、等级与局限

  • 证据类型:随机对照试验的荟萃分析。
  • 局限:作者认为需进一步开展围手术期输血策略的试验。

对床旁实践的改变

  • 作者认为限制性输血策略的安全性在重症患者与围手术期患者间可能不同。
  • 作者认为需进一步开展围手术期输血策略的试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To address the significant uncertainty as to whether transfusion thresholds for critical care versus surgical patients should differ.

DESIGN: Meta-analysis of randomized controlled trials.

SETTING: Medline, EMBASE, and Cochrane Library searches were performed up to 15 June 2016.

PATIENTS: Trials had to enroll adult surgical or critically ill patients for inclusion.

INTERVENTIONS: Studies had to compare a liberal versus restrictive threshold for the transfusion of allogeneic packed RBCs.

MEASUREMENTS AND MAIN RESULTS: The primary outcome was 30-day all-cause mortality, sub-grouped by surgical and critical care patients. Secondary outcomes included myocardial infarction, stroke, renal failure, allogeneic blood exposure, and length of stay. Odds ratios and weighted mean differences were calculated using random effects meta-analysis. To assess whether subgroups were significantly different, tests for subgroup interaction were used. Subgroup analysis by trials enrolling critically ill versus surgical patients was performed. Twenty-seven randomized controlled trials (10,797 patients) were included. In critical care patients, restrictive transfusion resulted in significantly reduced 30-day mortality compared with liberal transfusion (odds ratio, 0.82; 95% CI, 0.70-0.97). In surgical patients, a restrictive transfusion strategy led to the opposite direction of effect for mortality (odds ratio, 1.31; 95% CI, 0.94-1.82). The subgroup interaction test was significant (p = 0.04), suggesting that the effect of restrictive transfusion on mortality is statistically different for critical care (decreased risk) versus surgical patients (potentially increased risk or no difference). Regarding secondary outcomes, for critically ill patients, a restrictive strategy resulted in reduced risk of stroke/transient ischemic attack, packed RBC exposure, transfusion reactions, and hospital length of stay. In surgical patients, restrictive transfusion resulted in reduced packed RBC exposure.

CONCLUSIONS: The safety of restrictive transfusion strategies likely differs for critically ill patients versus perioperative patients. Further trials investigating transfusion strategies in the perioperative setting are necessary.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Chong MA, Krishnan R, Cheng D, et al. Should Transfusion Trigger Thresholds Differ for Critical Care Versus Perioperative Patients? A Meta-Analysis of Randomized Trials. Crit Care Med. 2018. PMID: 29189348. doi:10.1097/CCM.0000000000002873

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。